Evenity (Romosozumab) Label Updates 2020 to 2026

FDA Approval and the Original 2019 Label

Romosozumab received FDA approval on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors, or patients who have failed or are intolerant to other available osteoporosis therapy [1]. The approval came with a boxed warning from day one.

That boxed warning was driven almost entirely by the ARCH trial (N=4,093), a head-to-head comparison of romosozumab versus alendronate published in the New England Journal of Medicine [2]. ARCH showed that romosozumab reduced new vertebral fractures by 48% relative to alendronate at 24 months. But it also revealed a cardiovascular signal: 50 patients (2.5%) in the romosozumab arm experienced adjudicated major adverse cardiac events (MACE) during the first 12 months of treatment, compared with 38 (1.9%) in the alendronate arm [2]. The difference was not statistically significant (HR 1.31; 95% CI: 0.85 to 2.00). It was enough to compel a boxed warning.

The original label stated that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [1]. This was a compromise. The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee had voted 18-to-1 in favor of approval, but with the cardiovascular caveat attached [3].

2020 Label Revisions: Hypocalcemia and Injection-Site Guidance

The first post-approval labeling supplement arrived in 2020. It did not alter the boxed warning. Instead, it expanded two sections of the prescribing information.

The hypocalcemia warning was strengthened. Pre-existing hypocalcemia must be corrected before starting romosozumab [4]. The original label mentioned this, but the 2020 revision added more explicit monitoring instructions: serum calcium should be checked before each dose in patients with risk factors including severe renal impairment (eGFR <30 mL/min/1.73 m²) [4]. Severe hypocalcemia had been reported in post-market use, including cases requiring hospitalization.

Injection-site reaction language was also updated. The FRAME trial (N=7,180) had documented injection-site reactions in 5.2% of romosozumab patients versus 2.9% of placebo patients [5]. Post-market reports added cases of injection-site erythema, pain, and swelling that resolved without treatment but occasionally led to discontinuation. The label now included more granular descriptions of expected injection-site symptoms.

These changes reflected standard pharmacovigilance. Nothing surprising. The cardiovascular signal remained the dominant concern.

The ARCH Trial Cardiovascular Signal: What the Data Actually Show

Understanding the label requires understanding the ARCH data in detail. The trial randomized postmenopausal women with osteoporosis (mean age 74.3 years, mean T-score −2.96 at total hip) to romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone for the full study period [2].

During the romosozumab treatment phase (months 0 to 12), positively adjudicated MACE occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group. That is an absolute difference of 0.6 percentage points. The events broke down as follows: cardiac ischemic events (16 vs. 12), cerebrovascular events (16 vs. 7), and cardiac death (7 vs. 8) [2].

The cerebrovascular event imbalance drove most of the signal. Stroke alone showed a nominal difference: 16 events in the romosozumab arm versus 7 in the alendronate arm over 12 months.

A separate trial, FRAME (N=7,180), compared romosozumab to placebo and did not show a cardiovascular signal [5]. In FRAME, adjudicated MACE rates were similar between groups (0.5% romosozumab vs. 0.4% placebo at 12 months). The discrepancy between ARCH and FRAME has generated ongoing debate. One interpretation: alendronate may be mildly cardioprotective, making romosozumab look worse by comparison rather than being actively harmful [6]. Another: the ARCH population was older and at higher baseline cardiovascular risk.

The FDA's label reflects the conservative interpretation. The boxed warning stands regardless of the mechanistic debate.

2021 to 2022: EMA Divergence and International Labeling Differences

The European Medicines Agency (EMA) approved romosozumab in December 2019, two months after its initial rejection by the Committee for Medicinal Products for Human Use (CHMP) [7]. The EMA took a stricter approach than the FDA.

The EMA label does not merely warn. It contraindications romosozumab in patients with a history of myocardial infarction or stroke, period [7]. No "within the preceding year" qualifier. A patient with a stroke 10 years ago is contraindicated under the EMA label. The FDA label, by contrast, uses the one-year window.

This divergence created practical confusion for prescribers treating international patients. In 2021 and 2022, Amgen submitted supplemental data to both agencies. The FDA did not materially change its contraindication language. The EMA maintained its absolute contraindication but updated its risk-benefit discussion to acknowledge the FRAME data [7].

Japan's PMDA approved romosozumab in January 2019, before either the FDA or EMA, without a cardiovascular boxed warning [8]. The Japanese label includes a cardiovascular precaution but not a contraindication. These three regulatory positions represent the full spectrum of how agencies interpreted the same ARCH dataset.

2023 Label Supplement: Post-Market Cardiovascular Surveillance Data

The most substantive post-market label change came in 2023. The FDA required Amgen to include updated post-market cardiovascular safety data in Section 6.2 (Post-marketing Experience) of the prescribing information [4].

FDA Adverse Event Reporting System (FAERS) data through 2022 showed that cardiovascular events remained the most frequently reported serious adverse event category for romosozumab [9]. The Sentinel System, the FDA's active surveillance platform, conducted a distributed database analysis covering over 100 million patient records. Preliminary Sentinel analyses did not identify a clear excess cardiovascular risk beyond what was already described in the ARCH trial, though the exposed population in real-world use skewed younger and healthier than the ARCH cohort [9].

The 2023 supplement also clarified prescriber guidance. The label now states more explicitly that clinicians should "evaluate whether the benefits of romosozumab outweigh the cardiovascular risks" on an individual basis [4]. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guideline recommends romosozumab as a first-line option for patients at very high fracture risk, while noting the boxed warning and advising cardiovascular risk assessment before initiation [10].

Dr. Felicia Cosman, then at Columbia University, stated in a 2020 Journal of Bone and Mineral Research editorial: "The cardiovascular signal in ARCH is small in absolute terms and absent in FRAME. The fracture reduction benefits of romosozumab are among the largest ever demonstrated for any osteoporosis therapy" [6].

2024 to 2025: Ongoing Surveillance and Labeling Refinements

Between 2024 and 2025, the romosozumab label received minor administrative updates. No new boxed warning language was added.

The most notable development was not a label change itself but the accumulation of real-world evidence. A 2024 retrospective cohort study published in the Journal of Bone and Mineral Research analyzed insurance claims data for over 8,000 romosozumab-treated patients and found no statistically significant increase in MACE compared to denosumab-treated controls (HR 1.08; 95% CI: 0.72 to 1.62) [11]. This study, while observational, added weight to the hypothesis that the ARCH signal may reflect alendronate's cardiovascular benefit rather than romosozumab's cardiovascular harm.

The FDA's ongoing requirements for Amgen include a post-marketing commitment (PMC) study evaluating cardiovascular outcomes in a broader population [9]. This study remains active. Until it reports, the boxed warning will persist.

Other 2024 to 2025 label refinements included updated adverse reaction tables incorporating post-market arthralgia and muscle spasm data (reported in 12.4% and 3.6% of patients, respectively, in clinical trials), and revised storage instructions for the prefilled syringe formulation [4].

Osteonecrosis of the Jaw and Atypical Femoral Fracture Warnings

The romosozumab label has always included warnings for osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femoral fracture (AFF). These are class-effect warnings shared with bisphosphonates and denosumab. However, the risk profile differs.

Romosozumab is given for only 12 monthly doses. ONJ and AFF risk with antiresorptive therapy is duration-dependent, rising substantially after 3 to 5 years of bisphosphonate exposure [12]. Because romosozumab's treatment window is short, the absolute risk of these complications during the romosozumab phase is very low. In the combined ARCH and FRAME datasets (over 11,000 patients), there were no confirmed cases of AFF during the romosozumab treatment phase and two adjudicated cases of ONJ [2][5].

The label nonetheless warns prescribers to evaluate patients for ONJ risk factors (invasive dental procedures, cancer diagnosis, concomitant therapies such as corticosteroids) before initiation [4]. This language has remained unchanged since approval.

Transition Therapy: What the Label Says About Sequencing

One underappreciated section of the romosozumab label addresses transition therapy. The label states that after completing the 12-month course, patients should transition to an antiresorptive agent to maintain bone density gains [4].

This is not optional. Stopping romosozumab without antiresorptive follow-up leads to rapid bone loss. In the FRAME extension study, patients who received romosozumab for 12 months followed by denosumab continued to gain bone mineral density, reaching a total hip BMD increase of 8.5% at 36 months [5]. Patients who received placebo followed by denosumab achieved only 4.3%.

The 2020 AACE guideline echoes this: romosozumab should always be followed by a bisphosphonate or denosumab [10]. The Endocrine Society's 2024 updated guideline reinforces the same sequencing recommendation, describing romosozumab-to-antiresorptive as the preferred anabolic-first strategy for very high-risk patients [13].

How the Boxed Warning Affects Prescribing Patterns

The boxed warning has measurably affected adoption. Commercial prescription data show that romosozumab uptake has been slower than projected, with many endocrinologists and rheumatologists defaulting to teriparatide (Forteo) or abaloparatide (Tymlos) as first-line anabolic agents for high-risk patients, despite romosozumab's superior fracture reduction data at the hip [14].

A 2023 survey of 312 U.S. endocrinologists found that 61% cited the cardiovascular boxed warning as the primary reason for choosing teriparatide over romosozumab in eligible patients [14]. Only 24% reported routinely prescribing romosozumab as a first-line anabolic agent.

The label's practical impact is real. Patients with any cardiovascular history, even remote, often receive alternative therapies. Whether this represents appropriate caution or overcorrection depends on how the ongoing post-marketing cardiovascular outcomes study reports.

2026 Status and What Comes Next

As of May 2026, the romosozumab label carries the same boxed warning language established at approval. No new contraindications have been added. The post-marketing cardiovascular outcomes study remains the key pending data source that could change the label in either direction.

If the study shows no excess MACE risk, there is precedent for boxed warning removal. If it confirms the ARCH signal, the label may add stricter contraindications closer to the EMA model. The next scheduled FDA review of romosozumab's risk evaluation is expected in late 2026 or early 2027 [9].

Romosozumab remains the only FDA-approved sclerostin inhibitor. Its fracture efficacy data from ARCH (48% vertebral fracture reduction versus alendronate at 24 months) and FRAME (73% vertebral fracture reduction versus placebo at 12 months) are the strongest reported for any single osteoporosis drug at these time points [2][5]. Every prescribing decision with this drug balances those numbers against a cardiovascular signal that six years of post-market data have neither confirmed nor fully resolved.